State Laws: Prior Authorization as Well as Biomarkers

Discoveries in Health Policy published an analysis examining the intersection of state prior authorization reform laws and biomarker testing access legislation. This convergence reflects a growing recognition among state lawmakers that prior authorization requirements can function as barriers to evidence-based medicine — and that biomarker-guided treatment decisions deserve protection from administrative gatekeeping.

For physician practices, particularly those in oncology, genomics, pathology, and other specialties where biomarker testing informs treatment decisions, the emerging legislative landscape creates new protections that may reduce denial exposure for medically necessary diagnostic testing.

The Intersection Explained

Biomarker testing — including genomic sequencing, molecular profiling, and companion diagnostics — is increasingly central to evidence-based treatment decisions in oncology and other fields. Treatment guidelines from NCCN, ASCO, and other professional organizations routinely recommend biomarker testing to guide therapy selection, particularly for targeted therapies and immunotherapies.

Despite guideline support, biomarker testing frequently encounters prior authorization requirements and denials. Payers may deny biomarker tests on grounds of medical necessity, experimental status, or failure to meet payer-specific criteria that differ from clinical guidelines. These denials delay treatment decisions and can result in patients receiving less targeted therapies while the denial is contested.

State legislatures are responding by connecting two legislative threads: prior authorization reform (aimed at reducing administrative barriers broadly) and biomarker access legislation (aimed at ensuring coverage for guideline-recommended testing). The intersection of these threads creates legislation that specifically protects biomarker testing from prior authorization barriers.

What the Legislation Looks Like

The emerging state laws vary in specifics but share several common elements:

• Coverage mandates for guideline-recommended testing. Some states require insurers to cover biomarker tests that are recommended by nationally recognized clinical guidelines, removing the payer's discretion to deny tests that meet guideline criteria.
• PA exemptions for biomarker testing. Some legislation exempts biomarker testing from prior authorization requirements entirely, or from PA when the test is ordered in accordance with clinical guidelines.
• Accelerated PA review timelines. Where PA for biomarker testing is still required, some states mandate shorter review windows, recognizing that delays in diagnostic testing delay treatment decisions.
• Prohibition on step therapy for diagnostics. Some states prohibit payers from requiring less specific tests before authorizing more comprehensive biomarker testing, when clinical guidelines support the comprehensive approach.

Implications for Denial Management

For practices that order biomarker testing, the evolving legislative landscape has direct implications for how denials should be managed:

When a biomarker test is denied, the first step should be to determine whether the test is recommended by nationally recognized clinical guidelines. If it is, the appeal should prominently cite the guideline recommendation and explain how the test applies to the specific patient's clinical situation. Guideline-backed testing is increasingly protected by both state legislation and payer medical policies that reference guidelines.

Practices should identify whether their state has enacted biomarker coverage or PA reform legislation that applies to the denied test. If state law requires coverage for guideline-recommended biomarker testing, the denial may violate state law — and the appeal should reference the specific statutory provision.

For practices in states without biomarker-specific legislation, the general prior authorization reform landscape may still provide protections. Gold-card exemptions, PA response time requirements, and transparency mandates all apply to biomarker testing PA alongside other service categories.

The Clinical-Administrative Tension

Biomarker testing denials represent one of the clearest examples of the tension between clinical science and administrative policy. When a payer denies a test that NCCN guidelines recommend for a specific cancer type and stage, the payer is effectively second-guessing the clinical evidence base. The denial may be based on the payer's own medical policy, which may not reflect the most current clinical evidence.

This tension is what has driven state legislatures to act. The legislative response — connecting PA reform with biomarker access — recognizes that prior authorization, when applied to evidence-based diagnostics, can function as a barrier to the standard of care rather than a quality safeguard.

Staying Current

The biomarker access legislation landscape is evolving rapidly. Practices that order biomarker testing should monitor legislative developments in their state, maintain current knowledge of guideline recommendations for the tests they order, and build appeal templates that incorporate both the clinical evidence and any applicable statutory protections. The legislative trend favors biomarker access — practices that stay current can leverage these protections to reduce denial rates for diagnostic testing that their patients need.